Economic evidence for licensed ready‐to‐administer intravenous products compared with standard vials and ampoules: a systematic review

Licensed ready-to-administer products are associated with fewer preparation errors, shorter preparation times and reduced drug waste, with plausible economic benefits. The certainty of this conclusion is limited by heterogeneous, largely non-randomised designs and context-specific costs. Evidence specific to the UK is sparse. Multicentre studies with standardised outcomes and robust micro-costing are needed to define clinical impact, budget impact and implementation requirements.